

# David Martnez-Cuadrn

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1216394/david-martinez-cuadron-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

333  
citations

11  
h-index

16  
g-index

47  
ext. papers

501  
ext. citations

4.5  
avg, IF

3.2  
L-index

#	Paper	IF	Citations
40	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1115-1153	3	55
39	A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 700-10	4.5	36
38	Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 305-18	2	24
37	Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1197-1206	1.9	23
36	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , <b>2012</b> , 118, 410-7	6.4	19
35	Pharmacogenomics and the treatment of acute myeloid leukemia. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1245-1278	2.8	17
34	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. <i>Current Drug Metabolism</i> , <b>2018</b> , 19, 55-74	3.5	16
33	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 228-240	5.1	15
32	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2081-2088	3	13
31	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <i>Blood Reviews</i> , <b>2020</b> , 44, 100675	11.1	11
30	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1989-2007	3	11
29	PLZF-RAR, NPM1-RAR, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
28	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , <b>2019</b> , 76, 1-10	2.7	9
27	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2358-2370	10.7	8
26	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1077-1084	3	7
25	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , <b>2021</b> ,	10.7	7
24	Evolving treatment patterns and outcomes in older patients (≥70 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , <b>2021</b> , 35, 1571-1585	10.7	7

23	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 197-218	3.8	6
22	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , <b>2021</b> , 106, 3079-3089	6.6	5
21	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , <b>2021</b> , 127, 2003-2014	6.4	5
20	Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019016	3.2	3
19	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 672-683	4.5	3
18	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , <b>2021</b> ,	7.8	3
17	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , <b>2021</b> , 5, 760-770	7.8	3
16	Real life outcomes of patients aged ≥5 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2720-2732	1.9	2
15	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1497-1508	3	2
14	Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , <b>2021</b> , 36, 612-620	3.2	2
13	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. <i>Blood</i> , <b>2020</b> , 136, 25-27	2.2	1
12	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.. <i>Expert Opinion on Emerging Drugs</i> , <b>2022</b> , 1-18	3.7	1
11	Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 227-235	3.2	1
10	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 1057-1065	2.8	1
9	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
8	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. <i>Pharmacoeconomics - Open</i> , <b>2019</b> , 3, 229-235	2.1	1
7	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 659-668	1.9	1
6	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. <i>Blood</i> , <b>2019</b> , 134, 648-648	2.2	0

5	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 724-733	3.8	○
4	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , <b>2022</b> , 115, 106821	2.7	○
3	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2727-2736	1.9	
2	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. <i>Leukemia Research</i> , <b>2020</b> , 92, 106352	2.7	
1	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation. <i>Future Oncology</i> , <b>2021</b> , 17, 215-227	3.6	